Erasca, Inc.
ERAS
Rank in Stocks
#3567
Erasca, Inc. is a biopharmaceutical company in the clinical development stage,... Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California.
Share Price
$13.68
Market Cap
$4.78B
Change (1 day)
2.13%
Change (1 year)
465.08%
Country
US
Trade Erasca, Inc. (ERAS)
Category
Healthcare
Earnings for Erasca, Inc. (ERAS)
Earnings in Jun 2026 TTM: $-287.22M
According to Erasca, Inc. latest financial reports the company's current earnings are $-287.22M. In 2023 the company made an earning of $-125.04M, an increase over its 2022 earnings that were of $-242.81M. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Erasca, Inc. from 2019 to 2026
Earnings at the end of each year
| Year | Earnings | Change |
|---|---|---|
| 2026 (TTM) | $-287.22M | 77.68% |
| 2024 | $-161.65M | 29.28% |
| 2023 | $-125.04M | -48.50% |
| 2022 | $-242.81M | 97.78% |
| 2021 | $-122.76M | 20.76% |
| 2020 | $-101.66M | 744.35% |
| 2019 | $-12.04M | 0.00% |
Earnings for similar companies or competitors
| Company | Earnings | Earnings Difference | Country |
|---|---|---|---|
| $5.27B | -1,936.52% |
US
|
|
| $-3.09B | 974.77% |
US
|
|
| $-4.02B | 1,298.29% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -779.14% |
NL
|
